As the US government continues to rapidly expand its efforts to prepare for bioterrorist attacks, companies and researchers in the proteomics sector are in a prime position to rake in cash.

In the past year, US Congress has increased its budget for biodefense research by $1.5 billion. In response, the NIH and other governmental organizations have begun funding a slew of expensive and ambitious projects across the country aimed at developing the ability to rapidly diagnose and treat diseases such as anthrax, smallpox, and even ebola.